Restricted accessResearch articleFirst published online 2022-8
Intensive Care Unit- Acquired Weakness and Hospital Functional Mobility Outcomes Following Invasive Mechanical Ventilation in Patients with COVID-19: A Single-Centre Prospective Cohort Study
Background: Acute physical function outcomes in ICU survivors of COVID-19 pneumonia has received little attention. Critically ill patients with COVID-19 infection who require invasive mechanical ventilation may undergo greater exposure to some risk factors for ICU-acquired weakness (ICUAW). Purpose: To determine incidence and factors associated with ICUAW at ICU discharge and gait dependence at hospital discharge in mechanically ventilated patients with COVID-19 pneumonia. Methods: Single-centre, prospective cohort study conducted at a tertiary hospital in Madrid, Spain. We evaluated ICUAW with the Medical Research Council Summary Score (MRC-SS). Gait dependence was assessed with the Functional Status Score for the ICU (FSS-ICU) walking subscale. Results: During the pandemic second wave, between 27 July and 15 December, 2020, 70 patients were enrolled. ICUAW incidence was 65.7% and 31.4% at ICU discharge and hospital discharge, respectively. Gait dependence at hospital discharge was observed in 66 (54.3%) patients, including 9 (37.5%) without weakness at ICU discharge. In univariate analysis, ICUAW was associated with the use of neuromuscular blockers (crude odds ratio [OR] 9.059; p = 0.01) and duration of mechanical ventilation (OR 1.201; p = 0.001), but not with the duration of neuromuscular blockade (OR 1.145, p = 0.052). There was no difference in corticosteroid use between patients with and without weakness. Associations with gait dependence were lower MRC-SS at ICU discharge (OR 0.943; p = 0.015), older age (OR 1.126; p = 0.001), greater Charlson Comorbidity Index (OR 1.606; p = 0.011), longer duration of mechanical ventilation (OR 1.128; p = 0.001) and longer duration of neuromuscular blockade (OR 1.150; p = 0.029). Conclusions: In critically ill COVID-19 patients, the incidence of ICUAW and acute gait dependence were high. Our study identifies factors influencing both outcomes. Future studies should investigate optimal COVID-19 ARDS management and impact of dyspnea on acute functional outcomes of COVID-19 ICU survivors.
WuCChenXCaiY, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. 2020;180(7):1‐11. doi:10.1001/jamaintermed.2020.0994
2.
LaiCCShihTPKoWCTangHJHsuehPR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020::105924. doi:10.1016/j.ijantimicag.2020.105924
3.
BottaMTsonasAMPillayJ, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19: a national, multicentre, observational cohort study. Lancet Respir Med. 20219(2):139–148. doi: 10.1016/j.ijantimicag.2020.105924.
4.
CourcelleRGaudrySSerckNBlonzGLascarrouJB, Grimaldi D. on behalf the COVADIS study group. Neuromuscular blocking agents for COVID-19 acute respiratory distress syndrome: a multicenter observational study. Crit Care. 2020;24(1):446.
5.
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
6.
LatronicoNBoltonCF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931‐941. doi:10.1016/s1474-4422(11)70178-8
7.
De JongheBBastuji-GarinSSharsharTOutinHBrochardL. Does ICU-acquired paresis lengthen weaning from mechanical ventilation?Intensive Care Med. 2004;30(6):1117‐1121. doi:10.1007/s00134-004-2174-z
8.
KelmensonDAHeldNAllenRR, et al. Outcomes of ICU patients with a discharge diagnosis of critical illness polyneuromyopathy: a propensity-matched analysis. Crit Care Med. 2017 Dec;45(12):2055‐2060. doi:10.1097/CCM.000000000002763
9.
DinglasVDAronson FriedmanLColantuoniE, et al. Muscle weakness and 5–year survival in acute respiratory distress syndrome survivors. Crit Care Med. 2017;45(3):446‐453. doi:10.1097/CCM.0000000000002208
10.
Van AerdeNMeerssemanPDebaveyeY, et al. Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study. Intensive Care Med. 2020;46(6):1184‐1193. doi:10.1007/s00134-020-05927-5
11.
HermansGVan MechelenHClerckxB, et al. Acute outcomes and 1-year mortality of intensive care unit–acquired weakness. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2014;190(4):410‐420. doi:10.1164/rccm.201312-2257OC
12.
WatanabeSKotaniTTaitoS, et al. Determinants of gait independence after mechanical ventilation in the intensive care unit: a Japanese multicenter retrospective exploratory cohort study. J Intensive Care. 2019;Nov 27(7):53. doi:10.1186/s40560-019-0404-2
13.
HerridgeMSTanseyCMMattéA, et al. Canadian Critical care trials group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293−2304. https://doi.org/10.1056/NEJMoa1011802 doi:10.1056/NEJMoa1011802
14.
FanEDowdyDWColantuoniE, et al. Physical complications in acute lung injury survivors: a 2–year longitudinal prospective study. Crit Care Med . 2014;42(4):849-859. doi:10.1097/ccm.0000000000000040
15.
ThomasSMehrholzJ. Health-related quality of life, participation, and physical and cognitive function of patients with intensive care unit-acquired muscle weakness 1 year after rehabilitation in Germany: the GymNAST cohort study. BMJ Open. 2018;8(7):e020163. doi:10.1136/bmjopen-2017-020163
16.
González-SeguelFCornerEJMerino-OsorioC. International classification of functioning, disability, and health domains of 60 physical functioning measurement instruments used during the adult intensive care unit stay: a scoping review. Phys Ther. 2019;99(5):627-640. doi:10.1093/ptj/pzy158
17.
TymkewHNorrisTArroyoCSchallomM. The use of physical therapy ICU assessments to predict discharge home. Crit Care Med. 2020;48(9):1312‐1318. doi:10.1097/CCM.0000000000004467
18.
SolversonKJGrantCDoigCJ. Assessment and predictors of physical functioning post-hospital discharge in survivors of critical illness. Ann Intensive Care. 2016;6(1):92. doi:10.1186/s13613-016-0187-8
ThorntonJ. COVID-19: the challenge of patient rehabilitation after intensive care. Br Med J.2020;May 6, 369. doi:10.1136/bmj.m1787
21.
SimpsonRRobinsonL. Rehabilitation after critical illness in people with COVID-19 infection. Am J Phys Med Rehabil. 2020; 99(6):470‐474. doi:10.1097/PHM.0000000000001443
22.
VanhorebeekILatronicoNVan den BergheG. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637‐653. doi:10.1007/s00134-020-05944-4
23.
von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495‐1499. doi:10.1016/j.ijsu.2014.07.013
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8.
26.
KnausWADraperEAWagnerDPZimmermanJE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818‐829. doi:10.1097/00003246-198510000-00009
27.
VanpeeGHermansGSegersJGosselinkR. Assessment of limb muscle strength in critically ill patients: a systematic review. Crit Care Med. 2014;42(3):701‐711. doi:10.1097/CCM.0000000000000030.
28.
StevensRDMarshallSACornblathDR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 suppl):S299‐S308. doi:10.1097/CCM.0b013e3181b6ef67
29.
González-SeguelFCamus-MolinaALeppeJ, et al. Chilean Version of the functional Status score for the intensive care unit: a translation and cross-cultural adaptation. Medwave. 2019;19(01):e7439. doi:10.5867/medwave.2019.01.7439
30.
COVID-19 Consortium, Van AerdeNVan den BergheGWilmerAGosselinkRHermansG. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020;46(11):2083‐2085. doi:10.1007/s00134-020-06244-7.
31.
MoonenHPFXStrookappeBZantenARH. Physical recovery of COVID-19 pneumosepsis intensive care survivors compared with non-COVID pneumosepsis intensive care survivors during post–intensive care hospitalization: the RECOVID retrospective cohort study. J Parenter Enter Nutr. 2021;Aug(3):10.1002/jpen.2242. doi:10.1002/jpen.2242
32.
McWilliamsDWeblinJHodsonJ, et al. Rehabilitation levels in COVID-19 patients admitted to intensive care requiring invasive ventilation: an observational study. Ann Am Thorac Soc.2020;18(122):129. doi: 10.1513/AnnalsATS.202005-560OC.
33.
MedrinalCPrieurGBonnevieT, et al. Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors. BMC Anesthesiol2021;21(1):64. doi:10.1186/s12871-021-01274-0
34.
PapazianLPJean-MarieFArnaudG, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/nejmoa1005372
35.
The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997‐2008. doi:10.1056/NEJMoa1901686.
36.
NaukaPCChenJTShilohALEisenLAFeinDG. Practice, outcomes, and complications of emergent endotracheal intubation by critical care practitioners during the COVID-19 pandemic. Chest.2021;160(6):2112-2122. doi:10.1016/j.chest.2021.06.008
37.
WongtangmanKSanterPWachtendorfLJ, et al. Association of sedation, coma, and in-hospital mortality in mechanically ventilated patients with coronavirus disease 2019–related acute respiratory distress syndrome: a retrospective cohort study*. Crit Care Med. 2021;49(9):1524‐1534. doi:10.1097/CCM.0000000000005053
38.
SpanglerJMartleyTJSchieberTMohamedAWoodsM. Assessment of narcotic, sedative, and neuromuscular blocker needs of patients with COVID-19 requiring invasive mechanical ventilation. Am J Health Syst Pharm. 2021;78(13):1168‐1170. doi:10.1093/ajhp/zxab055.
39.
FerrandoCSuarez-SipmannFMellado-ArtigasR, et al. COVID-19 Spanish ICU network. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020;46(12):2200−2211. doi:10.1007/s00134-020-06192-2
40.
BellaniGLaffeyJGPhamT, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788‐800. http://doi.org/10.1001/jama.2016.0291. Erratum in: JAMA. 2016 Jul 19;316(3):350. Erratum in: JAMA. 2016 Jul 19;316(3):350.
41.
DuanEHAdhikariNKJD’AragonF, et al. Management of acute respiratory distress syndrome and refractory hypoxemia. A multicenter observational study. Ann Am Thorac Soc. 2017;14(12):1818‐1826. doi:10.1513/AnnalsATS.201612-1042OC
42.
GriffithsMJDMcAuleyDFPerkinsGD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420. doi:10.1136/bmjresp-2019-000420
43.
PapazianLAubronCBrochardL, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69. doi:10.1186/s13613-019-0540-9
44.
PriceDRMikkelsenMEUmscheidCAArmstrongEJ. Neuromuscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and meta-analysis. Crit Care Med. 2016;44(11):9. doi:10.1097/ccm.0000000000001839
45.
TarazanNAlshehriMSharifS, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials. Intensive Care Med Exp. 2020;8(1):61. doi:10.1186/s40635-020-00348-6
46.
Garnacho-MonteroJAmaya-VillarRGarcía-GarmendíaJLMadrazo-OsunaJOrtiz-LeybaC. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med. 2005;33(2):6. doi: 10.1097/01.ccm.0000153521.41848.7e.
47.
LönnqvistPABellMKarlssonTWiklundLHöglundASLarssonL. Does prolonged propofol sedation of mechanically ventilated COVID-19 patients contribute to critical illness myopathy?Br J Anaesth. 2020;125(3):e334‐e336. doi:10.1016/j.bja.2020.05.056
48.
YangT. Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Crit Care. 2018;22(1):187. doi:10.1186/s13054-018-2111-0
MusheyevBBorgLJanowiczR, et al. Functional status of mechanically ventilated COVID-19 survivors at ICU and hospital discharge. J Intensive Care. 2021;9(1):31. doi:10.1186/s40560-021-00542-y
52.
CurciCPisanoFBonacciE, et al. A. Early rehabilitation in post-acute COVID-19 patients: data from an Italian COVID-19 rehabilitation unit and proposal of a treatment protocol. Eur J Phys Rehabil Med. 2020;56(5):633–641. doi:10.23736/S1973-9087.20.06339-X
53.
TayMRJOngPLPuahSHThamSL. Acute functional outcomes in critically ill COVID-19 patients. Front Med. 2021;Jan 18(7):615997. doi:10.3389/fmed.2020.615997
54.
EggmannSLuderGVerraMLIrincheevaIBastiaenenCHGJakobSM. Functional ability and quality of life in critical illness survivors with intensive care unit acquired weakness: a secondary analysis of a randomised controlled trial. Scherag A, ed. PLOS ONE. 2020;15(3):e0229725. doi:10.1371/journal.pone.0229725
55.
HerridgeMSMatte-MartynADiaz-GranadosNAl-SaidiFGuestCBCookD. One-Year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683-693. doi:10.1056/NEJMoa022450
56.
BaxFLettieriCMariniA, et al. Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neurol Sci. 2021;42(6):2173‐2178. doi:10.1007/s10072-021-05110-8
57.
Lopez-LeonSWegman-OstroskyTPerelmanC, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi:10.1038/s41598-021-95565-8
58.
PfohERWozniakAWColantuoniE, et al. Physical declines occurring after hospital discharge in ARDS survivors: a 5-year longitudinal study. Intensive Care Med. 2016;42(10):1557‐1566. doi:10.1007/s00134-016-4530-1
59.
HermansGVan AerdeNMeerssemanP, et al. Five-year mortality and morbidity impact of prolonged versus brief ICU stay: a propensity score matched cohort study. Thorax. 2019;74(11):1037‐1045. doi:10.1136/thoraxjnl-2018-213020.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
